Company profile
PeptiMatrix | Defined, Animal-Free Hydrogels for 3D Cell Culture
PeptiMatrix delivers a defined peptide hydrogel platform for reproducible 3D cell culture in drug discovery and preclinical research.
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
We are in the process of setting up this company as a spin-out from our successful work developing a synthetic hydrogel for 3D cell culture. The process of spinning out has been supported by the BBSRC ICURe program which was undertaken by Dr John Curd after he completed a BBSRC-funded PhD in my lab. John's project involved working up chemical and enzymatic modification methods to allow in-gel functionalisation. John also streamlined the gel production progress and he developed trouble-shooting protocols to overcome some of the issues we had picked up from end users. The company has already attracted clients from academia and industry and we will be supporting these users to create bespoke 3D environments.
PeptiMatrix develops 3D culture growth technology for the drug testing industry, aiming to replace products derived from animals.
We have applied for Innovate funding to help establish the company after 2 successful rounds of BBSRC ICURe funding. We are working closely with Clive Roper as our commercial advisor, benefiting from his expertise in alternatives to animal use in the toxicology sector.
Dr John Curd (CEO) was nominated as a 'rising star' in the University of Nottingham 2024 Impact Awards. We are getting attention from industry leaders for our novel products and our excellent interactions with clients: https://www.fortunebusinessinsights.com/3d-cell-culture-market-109009
1 Jul 2023 to 30 Jun 2024
Current _in vitro_ models of development and disease typically fail to recapitulate the complexities of native tissue microenvironments, leading to a poor extrapolation of _in vitro_ findings to _in vivo_ relevance. This is a major contributing factor to the high attrition rate of new drugs moving from the lab to the clinic, leading to an estimated cost o...
